Supplementary Figures 1 - 6 from Therapeutic Potential of the Poly(ADP-ribose) Polymerase Inhibitor Rucaparib for the Treatment of Sporadic Human Ovarian Cancer
Year: 2023
Type: supplementary-materials
Abstract: PDF file - 603K, Supplemental Figure S1: Gene maps of the BRCA1 (A) and BRCA2 (B) CpG islands examined with bisulfite pyrosequencing. Supplemental Figure S2: Anchorage independent growth inhibition at 1μM rucaparib in soft agar. Of the 39 tested ovarian cancer cell lines 22 formed colonies in soft agar. Supplemental Figure S3: Microarray hybridizations of the cell line panel were performed using the Agilent Whole Human Genome 4X44K array chip.Supplemental Figure S4: Chemical structures of compounds used for the drug interaction studies.Supplemental Figure S5: A multivariate ANOVA model (accounting for type of chemotherapy, cell line, and drug concentration as single factors) indicates that the drug combination effects differed significantly between individual chemotherapeutic agents (P=0.010). Supplemental Figure S6: A multivariate ANOVA model (accounting for type of chemotherapy, cell line, and drug concentration as single factors) indicates that the best combination effect was achieved at lower topotecan (0.031 μM) and rucaparib (0.625 μM) drug concentrations (P=0.018).
Authors: Maike Ihnen, Christine zu Eulenburg, Teodora Kolarova, Jing Wei Qi, Kanthinh Manivong, Meenal Chalukya, Judy Dering, Lee Anderson, Charles Ginther, Alexandra Meuter, Boris Winterhoff, Siân Jones, Victor E. Velculescu, Natarajan Venkatesan, Hong-Mei Rong, Sugandha Dandekar, Nitin Udar, Fritz Jänicke, Gerrit Los, Dennis J. Slamon, Gottfried E. Konecny
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4362494137